Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

被引:2620
|
作者
Larkin, J. [1 ]
Chiarion-Sileni, V. [3 ]
Gonzalez, R. [8 ]
Grob, J-J [9 ]
Rutkowski, P. [12 ]
Lao, C. D. [13 ]
Cowey, C. L. [14 ]
Schadendorf, D. [15 ,16 ]
Wagstaff, J. [2 ]
Dummer, R. [17 ]
Ferrucci, P. F. [4 ]
Smylie, M. [18 ]
Hogg, D. [19 ]
Hill, A. [20 ]
Marquez-Rodas, I. [24 ,25 ]
Haanen, J. [26 ]
Guidoboni, M. [6 ]
Maio, M. [7 ]
Schoffski, P. [27 ]
Carlino, M. S. [21 ]
Lebbe, C. [10 ,11 ]
McArthur, G. [23 ]
Ascierto, P. A. [5 ]
Daniels, G. A. [28 ]
Long, G. V. [21 ,22 ]
Bastholt, L. [29 ]
Rizzo, J. I. [30 ]
Balogh, A. [30 ]
Moshyk, A. [30 ]
Hodi, F. S. [31 ]
Wolchok, J. D. [32 ,33 ]
机构
[1] Royal Marsden NHS Fdn Trust, 203 Fulham Rd, London SW3 6JJ, England
[2] Swansea Univ, Coll Med, Swansea, W Glam, Wales
[3] IRCCS, Oncol Inst Veneto, Padua, Italy
[4] IRCCS, European Inst Oncol, Milan, Italy
[5] Ist Nazl Tumori IRCCS Fdn Pascale, Naples, Italy
[6] IRCCS Ist Sci Romagnolo Studio Cura Tumori, Immunotherapy & Somat Cell Therapy Unit, Meldola, Italy
[7] Univ Hosp, Ctr Immunooncol Med Oncol & Immunotherapy, Siena, Italy
[8] Univ Colorado, Canc Ctr, Aurora, CO USA
[9] Aix Marseille Univ, Hop Timone, AP HM, Marseille, France
[10] Univ Paris, AP HP, INSERM, Dermatol,Unite 976, Paris, France
[11] St Louis Hosp, Ctr Invest Clin, Paris, France
[12] Maria Sklodowska Curie Inst, Oncol Ctr, Warsaw, Poland
[13] Univ Michigan, Ann Arbor, MI 48109 USA
[14] Baylor Charles A Sammons Canc Ctr, Texas Oncol, Dallas, TX USA
[15] Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany
[16] German Canc Consortium, Heidelberg, Germany
[17] Univ Spital, Zurich, Switzerland
[18] Cross Canc Inst, Edmonton, AB, Canada
[19] Princess Margaret Canc Ctr, Toronto, ON, Canada
[20] Tasman Oncol Res, Southport, Qld, Australia
[21] Univ Sydney, Melanoma Inst Australia, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[22] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
[23] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[24] Gen Univ Hosp Gregorio Maranon, Madrid, Spain
[25] Ctr Invest Biomed Red Oncol, Madrid, Spain
[26] Netherlands Canc Inst, Amsterdam, Netherlands
[27] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, Leuven, Belgium
[28] Univ Calif San Diego, Hlth La Jolla Moores, La Jolla, CA 92093 USA
[29] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[30] Bristol Myers Squibb, Princeton, NJ USA
[31] Dana Farber Canc Inst, Boston, MA 02115 USA
[32] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[33] Weill Cornell Med Coll, New York, NY USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2019年 / 381卷 / 16期
关键词
D O I
10.1056/NEJMoa1910836
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. Methods We randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo. The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group. Results At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63). Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group. No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone. No new late toxic effects were noted. Conclusions Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, with no apparent loss of quality of life in the patients who received regimens containing nivolumab.
引用
收藏
页码:1535 / 1546
页数:12
相关论文
共 50 条
  • [41] HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    Moshyk, A.
    Kotapati, S.
    VALUE IN HEALTH, 2019, 22 : S72 - S73
  • [42] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Rutkowski, Piotr
    Lao, Christopher D.
    Cowey, C. Lance
    Schadendorf, Dirk
    Wagstaff, John
    Dummer, Reinhard
    Ferrucci, Pier Francesco
    Smylie, Michael
    Butler, Marcus O.
    Hill, Andrew
    Marquez-Rodas, Ivan
    Haanen, John B. A. G.
    Guidoboni, Massimo
    Maio, Michele
    Schoffski, Patrick
    Carlino, Matteo S.
    Lebbe, Celeste
    McArthur, Grant
    Ascierto, Paolo A.
    Daniels, Gregory A.
    Long, Georgina, V
    Bas, Tuba
    Ritchings, Corey
    Larkin, James
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +
  • [43] Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal
    Wan, M. T.
    Ming, M. E.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (02) : 296 - 300
  • [44] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Potluri, Ravi
    Ranjan, Sandip
    Bhandari, Hitesh
    Johnson, Helen
    Moshyk, Andriy
    Kotapati, Srividya
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (1)
  • [45] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Ravi Potluri
    Sandip Ranjan
    Hitesh Bhandari
    Helen Johnson
    Andriy Moshyk
    Srividya Kotapati
    Experimental Hematology & Oncology, 8
  • [46] Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
    Postow, Michael A.
    Chesney, Jason
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David
    Salama, April K.
    Taylor, Matthew
    Ott, Patrick A.
    Rollin, Linda M.
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd D.
    Hodi, F. Stephen
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21): : 2006 - 2017
  • [47] Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064).
    Weber, Jeffrey S.
    Gibney, Geoffrey Thomas
    Sullivan, Ryan J.
    Sosman, Jeffrey Alan
    Slingluff, Craig L.
    Lawrence, Donald P.
    Logan, Theodore F.
    Schuchter, Lynn Mara
    Nair, Suresh
    Buchbinder, Elizabeth Iannotti
    Berghorn, Elmer
    Jiang, Joel
    Horak, Christine E.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Survival outcomes associated with fewer combination ipilimumab/nivolumab doses in advanced-stage melanoma.
    Ma, Vincent T.
    Sun, Yilun
    Sitto, Merna
    Waninger, Jessica
    Fecher, Leslie Anne
    Green, Michael
    Lao, Christopher D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
    Mason, Robert
    Dearden, Helen C.
    Nguyen, Bella
    Soon, Jennifer A.
    Smith, Jessica Louise
    Randhawa, Manreet
    Mant, Andrew
    Warburton, Lydai
    Lo, Serigne
    Meniawy, Tarek
    Guminski, Alexander
    Parente, Phillip
    Ali, Sayed
    Haydon, Andrew
    Long, Georgina V.
    Carlino, Matteo S.
    Millward, Michael
    Atkinson, Victoria G.
    Menzies, Alexander M.
    PIGMENT CELL & MELANOMA RESEARCH, 2020, 33 (02) : 358 - 365
  • [50] COMPARISON OF HEALTHCARE COSTS IN FRANCE OF COMBINATION NIVOLUMAB AND IPILIMUMAB TREATMENT VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Bregman, B.
    Moshyk, A.
    Johnson, H. M.
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    VALUE IN HEALTH, 2020, 23 : S441 - S441